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Over the last decade, numerous studies have demonstrated
that inflammation is involved in the cascade of events that
lead to renal complications in patients with diabetic kidney
disease [1]. Experimental studies highlighted the pathogenic
role of inflammatory processes at the cellular and molecular
levels. Observational studies have translated these findings to
the human situation and have consistently shown that diabetic
patients with higher levels of inflammatory markers in their
blood or urine are at higher risk of renal function decline.
These studies raise the possibility that anti-inflammatory
interventions may slow the progression of diabetic kidney
disease.
The question of whether anti-inflammatory interventions
protect the kidney is not new—the potential renoprotective
effects of non-steroidal anti-inflammatory drugs (NSAIDs)
were assessed in patients with proteinuria more than 30 years
ago. An observational study of patients with nephropathy and
proteinuria found that the incidence of doubling of serum
creatinine or chronic dialysis was significantly lower among
patients receiving indometacin [2]. These studies
hypothesised that treatment with NSAIDs, such as
indometacin or naproxen, confer renoprotection by reducing
intra-glomerular pressure through haemodynamic effects
[3, 4]. Whether anti-inflammatory properties contributed to
the alleged long-term renoprotective effects of NSAIDs could
not be determined at the time the studies were performed
because specific assays for inflammatory markers were not
available.
In recent years various novel inflammatory components
have been discovered. These inflammatory components often
interact and collectively form a complex interplay through
which inflammation contributes to the development and
progression of diabetic kidney disease [1]. The discovery of
these inflammatory components has spurred scientists to
develop new drugs targeting them. At the scientific meeting
of the EASD in September 2015 in Stockholm three Phase 2
studies on novel anti-inflammatory agents were presented at a
symposium entitled ‘Anti-inflammatory interventions in
diabetes’. The first study investigated the effect of emapticap
pegol (NOX-E36). Emapticap is a direct inhibitor of
monocyte chemotactic protein-1 (MCP-1, also referred to as
C-C motif chemokine ligand 2 or CCL2). MCP-1 is a
chemokine produced by many cell types, including
endothelial and epithelial cells as well as smooth muscle cells.
Binding of MCP-1 to its receptor, C-C motif chemokine
receptor 2 (CCR2), stimulates the release of monocytes from
bone marrow and activates the migration and translocation of
monocytes and macrophages [5]. Blockade of MCP-1 may
alleviate a proinflammatory state and it is thought that
intra-renal blockade of MCP-1 may preserve podocyte
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numbers as well as renal function. The Phase 2a study
presented by Hermann Haller at the EASD, and recently
published [6], was a randomised placebo-controlled
double-blind trial in 75 patients with type 2 diabetes and
micro- or macroalbuminuria. Emapticap or matched placebo
were administered subcutaneously twice weekly for a total
duration of 12 weeks. After 12 weeks’ treatment, emapticap
had non-significantly decreased albuminuria by 15%
(p = 0.22) [6]. Interestingly, the effects of emapticap on
albuminuria persisted during the 12-week observational study
period following the cessation of study medication [6].
The second study, presented by Dick de Zeeuw, also used a
drug that targeted the MCP-1 axis. The study tested the
albuminuria-lowering effect of the CCR2 antagonist CCX140-B
in patients with type 2 diabetes and macroalbuminuria. As
reported previously [7], 12 weeks’ treatment with CCX140-B
at doses of 5 mg/day decreased albuminuria by 18% relative to
placebo. The albuminuria-lowering effects persisted throughout
the 52-week follow-up period, and 4 weeks after study drug
discontinuation. Intriguingly, CCX140-B at doses of 10 mg/day
also decreased albuminuria during the first weeks of treatment,
but the effect dissipated during the 52-week follow-up period.
In the 10 mg arm, a statistically significant increase in MCP-1,
the endogenous ligand for CCR2, was also observed at the end
of the 52-week follow-up. Interestingly, a post hoc analysis
revealed that those patients with a higher increase in MCP-1
after 52 weeks showed a smaller decrease in albuminuria
response. These findings raise the possibility that the higher
increase in MCP-1 in the 10 mg arm competed with
CCX140-B for binding to the receptor and blunted the
albuminuria-lowering efficacy. With respect to safety,
CCX140-B was generally well tolerated.
The results for a third drug were presented by Frank
Brosius, who reported on baricitinib, a Janus kinase 1/2
(JAK1/2) inhibitor that is currently being tested in Phase 3
clinical trials for rheumatoid arthritis. In the last couple of
years it has become increasingly clear that the JAK–signal
transducers and activators of transcription (STAT) pathway
is involved in transmitting responses of cytokines and
chemokines to the nucleus in order to activate a range of
cellular responses, thereby mediating a proinflammatory
milieu [8]. As described in the review by Brosius et al in this
issue of Diabetologia [9], treatment with baricitinib at doses
ranging from 0.75 to 4 mg dose-dependently decreased
albuminuria. The effects were present after 3 months’
treatment and persisted after 6 months. Anaemia was the most
common reported side effect and occurred mainly with the
4 mg baricitinib dose.
Although these studies provide some indication that
anti-inflammatory strategies targeting the MCP-1/CCL2 or
the JAK–STAT pathway may be a fruitful approach to delay
the progression of diabetic kidney disease, many questions
remain unanswered. The first question that should be
addressed is whether a change in albuminuria is the right
surrogate measure to determine the efficacy of anti-
inflammatory drugs. Although albuminuria is often used in
Phase 2 clinical trials of diabetic kidney disease to assess drug
efficacy, it may be possible that other more specific
inflammatory markers are better surrogates to determine
efficacy. However, to the best of our knowledge there are no
data to prove that a drug-induced reduction in inflammatory
markers is associated with a reduction in hard renal endpoints.
In addition, it should be noted that, in theory, anti-
inflammatory drugs might not decrease albuminuria but may
still be renoprotective. It has been shown that albumin
re-uptake at the tubular level triggers toxic effects and
inflammatory responses [10]. This could mean that blocking
proinflammatory pathways downstream of albumin re-uptake
may prevent renal function loss without affecting albuminuria
itself. Clearly, further research is required to assess whether
albuminuria is the right surrogate biomarker for these agents
and whether more specific inflammatory biomarkers could be
better substitutes for end-stage renal disease.
Another question to be answered relates to the time course
of the anti-inflammatory and albuminuria-lowering effects.
MCP-1 inhibition with emapticap did not show an effect on
albuminuria during 12 weeks’ treatment relative to placebo,
but albuminuria levels tended to be lower during the 12 week
period after drug discontinuation compared with placebo. In
contrast, blockade of CCR2 (the endogenous receptor of
MCP-1) with CCX140-B decreased albuminuria after
12 weeks’ treatment and the effect was already present after
4 weeks’ treatment. The discrepancy between these different
time courses of effects is unclear and may relate to the
different pharmacochemical and physical properties of the
drugs, or could even be a chance finding given the low
number of patients in these studies and the high variability
in albuminuria in the placebo arms. A better understanding
of the time course of effect, particularly for emapticap, is
required before large outcome studies are initiated.
A third question that should be addressed is whether the
anti-inflammatory agents exert structural effects and improve
underlying disease pathophysiology. In all three studies the
albuminuria-lowering effect persisted after study drug
discontinuation. Specifically, even after 12 weeks’
discontinuation of emapticap, albuminuria did not return to
baseline levels. These long-lasting effects suggest that the
anti-inflammatory drugs may improve underlying
pathophysiology. However, the 4-week follow-up period after
cessation of treatment in the CCX140-B and baricitinib
studies was too short to characterise long-lasting effects.
Additional data supporting potential structural improvements
in kidney pathology by these agents, for example, through
imaging studies, are required and would also improve our
understanding of the mechanisms of action of these anti-
inflammatory agents.
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How do we move on from here? Diabetic kidney dis-
ease remains associated with a high residual risk, and
novel treatments to improve the prognosis of these high
risk patients are highly desirable. The studies presented
at the EASD meeting in Stockholm provide some hope
that in the future novel treatments that employ other
pathways beyond the well-known renin–angiotensin sys-
tem may become available. However, there are still many
questions to be answered, the most important of which is
probably: how effective are these anti-inflammatory
agents at preventing end-stage renal disease?
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